Literature DB >> 11278379

Cell surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein.

A G Sarafanov1, N M Ananyeva, M Shima, E L Saenko.   

Abstract

We have demonstrated previously that catabolism of a coagulation factor VIII (fVIII) from its complex with von Willebrand factor (vWf) is mediated by low density lipoprotein receptor-related protein (LRP) (Saenko, E. L., Yakhyaev, A. V., Mikhailenko, I., Strickland, D. K., and Sarafanov, A. G. (1999) J. Biol. Chem. 274, 37685-37692). In the present study, we found that this process is facilitated by cell surface heparan sulfate proteoglycans (HSPGs). This was demonstrated by simultaneous blocking of LRP and HSPGs in model cells, which completely prevented fVIII internalization and degradation from its complex with vWf. In contrast, the selective blocking of either receptor had a lesser effect. In vivo studies of clearance of (125)I-fVIII-vWf complex in mice also demonstrated that the simultaneous blocking of HSPGs and LRP led to a more significant prolongation of fVIII half-life (5.5-fold) than blocking of LRP alone (3.5-fold). The cell culture and in vivo experiments revealed that HSPGs are also involved in another, LRP-independent pathway of fVIII catabolism. In both pathways, HSPGs act as receptors providing the initial binding of fVIII-vWf complex to cells. We demonstrated that this binding occurs via the A2 domain of fVIII, since A2, but not other portions of fVIII or isolated vWf, strongly inhibited cell surface binding of fVIII-vWf complex, and the affinities of A2 and fVIII-vWf complex for the cells were similar. The A2 site involved in binding to heparin was localized to the region 558-565, based on the ability of the corresponding synthetic peptide to inhibit A2 binding to heparin, used as a model for HSPGs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11278379     DOI: 10.1074/jbc.M008046200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  Heparan sulphate proteoglycan and the low-density lipoprotein receptor-related protein 1 constitute major pathways for neuronal amyloid-beta uptake.

Authors:  Takahisa Kanekiyo; Juan Zhang; Qiang Liu; Chia-Chen Liu; Lijuan Zhang; Guojun Bu
Journal:  J Neurosci       Date:  2011-02-02       Impact factor: 6.167

2.  Mapping the binding region on the low density lipoprotein receptor for blood coagulation factor VIII.

Authors:  James H Kurasawa; Svetlana A Shestopal; Elena Karnaukhova; Evi B Struble; Timothy K Lee; Andrey G Sarafanov
Journal:  J Biol Chem       Date:  2013-06-10       Impact factor: 5.157

3.  Re-examination of CD91 function in GRP94 (glycoprotein 96) surface binding, uptake, and peptide cross-presentation.

Authors:  Angela R Jockheck-Clark; Edith V Bowers; Mariam B Totonchy; Julie Neubauer; Salvatore V Pizzo; Christopher V Nicchitta
Journal:  J Immunol       Date:  2010-11-03       Impact factor: 5.422

4.  "Novel strategies to Improve Recombinant Factor VIII Production and its in vivo Recovery".

Authors:  Raghuveer Prabhu
Journal:  Indian J Hematol Blood Transfus       Date:  2010-10-14       Impact factor: 0.900

5.  The endothelial lectin clearance receptor CLEC4M binds and internalizes factor VIII in a VWF-dependent and independent manner.

Authors:  Laura L Swystun; Colleen Notley; Ilinca Georgescu; Jesse D Lai; Kate Nesbitt; Paula D James; David Lillicrap
Journal:  J Thromb Haemost       Date:  2019-03-19       Impact factor: 5.824

6.  The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells.

Authors:  Bagirath Gangadharan; Mathieu Ing; Sandrine Delignat; Ivan Peyron; Maud Teyssandier; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941

Review 7.  Low-density lipoprotein receptor-related protein-1: role in the regulation of vascular integrity.

Authors:  Dudley K Strickland; Dianaly T Au; Patricia Cunfer; Selen C Muratoglu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-02-06       Impact factor: 8.311

8.  Value of ABO blood group in predicting the severity of children with Crimean-Congo hemorrhagic fever.

Authors:  Ahmet Sami Güven; Enver Sancakdar; Ali Kaya; Elif Bilge Uysal; Mehmet Burhan Oflaz; Fatih Bolat; Hekim Karapınar; Elif Koç; Füsun Dilara Icagasioglu
Journal:  Int J Clin Exp Med       Date:  2014-02-15

9.  Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival.

Authors:  Sandra L Haberichter; Michael Balistreri; Pamela Christopherson; Patricia Morateck; Stefana Gavazova; Daniel B Bellissimo; Marilyn J Manco-Johnson; Joan Cox Gill; Robert R Montgomery
Journal:  Blood       Date:  2006-07-11       Impact factor: 22.113

10.  Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.

Authors:  Y Dargaud; A Pavlova; S Lacroix-Desmazes; K Fischer; M Soucie; S Claeyssens; D W Scott; R d'Oiron; G Lavigne-Lissalde; G Kenet; C Escuriola Ettingshausen; A Borel-Derlon; T Lambert; G Pasta; C Négrier
Journal:  Haemophilia       Date:  2016-01       Impact factor: 4.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.